Category | Subcategory | Definition | |
---|---|---|---|
WHO Subtask 1. Assessing eligibility | Eligibility assessment | Using different mechanisms, such as LMP and pelvic bimanual versus ultrasound to determine eligibility for early MA | |
WHO Subtask 2: Administering the medications and managing the process and common side-effects | Clinical management | Safety and efficacy | Testing different clinical innovations and regimens for MA |
Feasibility | Practicability of administration of mifepristone-misoprostol or misoprostol-only regimens on MA in various situations and contexts | ||
Management of side effects and complications | Self-administration of medication and self-management of pain, bleeding, expulsion of the products of conception, and self-identification of the need to seek formal healthcare for potential complications | ||
Models of service delivery | Facility-based models | Assessment of different models of facility-based provision of MA | |
Information and counseling | Models of providing and receiving information on MA before undergoing the procedure | ||
Online and telemedicine provision | Provision or acquisition of MA pills and/or information about the procedure via website or via telemedicine, i.e. providers using telecommunications technology to interact with patients remotely | ||
Home use | Safety, effectiveness and experiences of administration of mifepristone-misoprostol or misoprostol-only regimens by an individual at home. This also includes partial self-administration | ||
Pharmacy provision | Documentation of sourcing of MA from pharmacists or pharmacies, regardless of the legal context | ||
WHO Subtask 3: Assessing completion of the procedure and the need for further clinic-based follow-up | Failure and adverse events related to MA | Prevalence and characteristics of adverse events, including failure and need for surgical intervention, hospital admission, blood transfusion, emergency department treatment, intravenous antibiotics administration, infection, and death, as follow-on events from cases of self-administration of combined regimen and/or misoprostol-only induced abortions | |
Post-abortion follow-up using β-hCG | Using serum hCG measurements for monitoring of abortion completion versus or in place of ultrasonography | ||
Models for post-abortion follow-up | Effectiveness of different types of MA service delivery follow-up options, e.g. home pregnancy test, checklists, bimanual or speculum examination by provider, telephone follow up etc. to assess completion | ||
Ultrasound | Techniques or technology associated with conducting and/or reading ultrasound as part of the MA process – only for completion | ||
Post-MA contraception | Take up, safety and acceptability of contraceptive methods after MA | ||
Other clinical | Prevalence | Analyses of proportions of a population experiencing (aspects of) MA; can include subgroup analyses, and association and correlations with other factors | |
MA in particular populations | Analyses of the safety, efficacy, acceptability and service delivery options for certain sub-groups of a given population | ||
Surgical vs. medical abortion | Comparison of surgical and MA regarding factors such as preference, access, acceptability, safety, efficacy etc | ||
Social science | Knowledge, attitudes and practices | Assessing the awareness, views and behaviors of different populations regarding MA among women, partners, providers and relevant others | |
Women's preferences and experiences with MA | Measure of preferences regarding MA among women who have used it | ||
Legal/policy context | Related to laws and policies governing MA | ||
Cost-effectiveness | Economic analyses of relative costs and outcomes of different aspects of the delivery and/or receipt of MA care // Documentation of the degree to which a specific aspect of MA is good value for the resources required |